Zen-ichi Terashita

This inventor holds 11 USPTO granted patents. Top assignees: Takeda Chemical Industries, Inc., Takeda Pharmaceutical Company Limited. Active years: 1996-2009.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Zen-ichi Terashita. Retrieved from https://idiyas.com/inventor/zen-ichi-terashita

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11

% Patents Active = 72.7

Average Co-Inventor Count = 3.5

ph-index = 6

Forward Citations = 96(Granted Patents)

Location History:

Toyonaka, JP (2001 - 2005)
Osaka, JP (1996 - 2009)

Company Filing History:

9 out of 1,858

Takeda Chemical Industries, Inc.

patents

2 out of 1,228

Takeda Pharmaceutical Company Limited

patents

Years Active: 1996-2009

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7582662 - Body weight gain inhibitor (2009-09-01),

2. 6974806 - Lipid-rich plaque inhibitors (2005-12-13),

3. 6680312 - Sulfonamide derivatives, their production and use (2004-01-20),

4. 6417213 - Tricyclic compound, their production and use (2002-07-09),

5. 6403595 - Sulfonamide derivatives, processes for producing the same and utilization thereof (2002-06-11),

6. 6359134 - Sulfonamide derivatives, their production and use (2002-03-19),

7. 6248766 - Tricyclic compounds, their production and use (2001-06-19),

8. 6242600 - 2-piperazinone-1-acetic acid derivatives and their use (2001-06-05),

9. 6020334 - Piperazinones, their production and use (2000-02-01),

10. 5935963 - Piperazinones, their production and use (1999-08-10),

11. 5550138 - Condensed thiadiazole derivative, method of its production, and use (1996-08-27),

Title: Innovations by Zen-ichi Terashita: A Journey of Impactful Inventions

Introduction

Zen-ichi Terashita is a notable inventor based in Toyonaka, Japan, recognized for his innovative contributions to pharmaceuticals. With a remarkable portfolio consisting of 11 patents, Terashita's work primarily focuses on addressing critical health issues through advanced biochemical solutions.

Latest Patents

One of his most significant recent inventions is the Body Weight Gain Inhibitor. This pharmaceutical agent comprises a compound exhibiting angiotensin II antagonistic activity or its prodrug or salt forms. The invention is designed to effectively suppress body weight gain, making it particularly valuable for patients undergoing treatments for diabetes and other related conditions without the risk of weight increase.

Another noteworthy patent is the Lipid-Rich Plaque Inhibitor. This invention offers a lipid-rich plaque regressing agent consisting of a compound represented by a specific formula. The complex structure involves cyclic hydrocarbons, heterocyclic rings, and aryl compounds, showcasing Terashita's ingenuity in designing effective treatments for cardiovascular health.

Career Highlights

Terashita's career is marked by his tenure at prominent pharmaceutical companies. He has worked with Takeda Chemical Industries, Inc. and Takeda Pharmaceutical Company Limited, where his expertise in pharmaceutical innovation has led to significant advancements in drug development.

Collaborations

Throughout his career, Zen-ichi Terashita has collaborated with notable coworkers, including Hiroyuki Tawada and Hideto Fukushi. These collaborations have fostered a dynamic environment for innovation, allowing for the exchange of ideas and collective problem-solving in the biomedical field.

Conclusion

In summary, Zen-ichi Terashita stands out as a leading inventor in the pharmaceutical industry, with a focus on creating impactful solutions for weight management and cardiovascular health. His 11 patents reflect his dedication to innovation and the betterment of healthcare, paving the way for future advancements in medical treatments.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]